Physician profile
Jack C Cole
NPI 1477549376
$6,961.95
in general payments reported to CMS, 2019-2025
33 companies · $428 in 2025
The $428 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $696 · 2020: $719 · 2021: $1,322 · 2022: $1,387 · 2023: $1,389 · 2024: $1,022 · 2025: $428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,839.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,838.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,639.99 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $623.96 | 2019-2023 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $561.40 | 2019-2025 | Stelara, Simponi Aria, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $549.58 | 2019-2025 | Entyvio, Eohilia |
| Pfizer INC. | $305.52 | 2019-2025 | |
| Genzyme Corporation | $215.69 | 2022-2025 | |
| Redhill Biopharma INC. | $214.02 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $212.67 | 2020-2024 | Dificid |
| Ironwood Pharmaceuticals, INC | $190.42 | 2019-2023 | Linzess |
| Regeneron Healthcare Solutions, INC. | $178.28 | 2022-2025 | Dupixent |
| Nestle Healthcare Nutrition INC. | $174.00 | 2021-2023 | |
| Phathom Pharmaceuticals, INC. | $172.15 | 2024 | Voquezna |
| Intercept Pharmaceuticals, INC. | $169.60 | 2019-2023 | Ocaliva |
| Celgene Corporation | $130.81 | 2021-2023 | Zeposia |
| Ardelyx, INC. | $91.32 | 2022-2024 | Ibsrela |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $66.28 | 2019-2022 | |
| Amgen INC. | $50.48 | 2022-2023 | Amjevita |
| Alfasigma USA, INC. | $47.15 | 2020 | |
| Madrigal Pharmaceuticals | $45.08 | 2025 | Rezdiffra |
| Aimmune Therapeutics, INC. | $40.20 | 2024 | |
| Ferring Pharmaceuticals INC. | $32.43 | 2020-2023 | Cimzia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.89 | 2023 | Cyltezo |
| Allergan, INC. | $26.78 | 2019-2020 | |
| Micro-Tech Endoscopy USA, INC. | $25.48 | 2022-2023 | Dat Closure Device |
| Daiichi Sankyo INC. | $24.01 | 2022 | |
| Lilly USA, LLC | $21.13 | 2024 | Omvoh |
| Sandoz INC. | $20.91 | 2024 | Hyrimoz |
| Ucb, INC. | $20.80 | 2019 | |
| Mauna Kea Technologies, INC. | $19.97 | 2021 | |
| Novo Nordisk INC | $19.43 | 2025 | Wegovy |
| Gilead Sciences, INC. | $15.60 | 2022 | |
| Endo Pharmaceuticals INC. | $15.46 | 2019 | |
| Olympus America INC. | $13.46 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Cole listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.